| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Retinopathy | 83 | 2025 | 168 | 23.170 |
Why?
|
| Angiogenesis Inhibitors | 109 | 2026 | 226 | 19.470 |
Why?
|
| Macular Edema | 61 | 2025 | 96 | 16.230 |
Why?
|
| Visual Acuity | 117 | 2026 | 707 | 15.430 |
Why?
|
| Wet Macular Degeneration | 37 | 2025 | 45 | 10.790 |
Why?
|
| Ranibizumab | 62 | 2026 | 76 | 10.260 |
Why?
|
| Macular Degeneration | 33 | 2025 | 127 | 10.240 |
Why?
|
| Vascular Endothelial Growth Factor A | 94 | 2026 | 444 | 10.080 |
Why?
|
| Intravitreal Injections | 106 | 2026 | 154 | 9.460 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 52 | 2026 | 103 | 9.440 |
Why?
|
| Tomography, Optical Coherence | 97 | 2026 | 573 | 9.370 |
Why?
|
| Recombinant Fusion Proteins | 53 | 2026 | 761 | 8.760 |
Why?
|
| Fluorescein Angiography | 70 | 2026 | 152 | 7.470 |
Why?
|
| Geographic Atrophy | 17 | 2025 | 24 | 7.320 |
Why?
|
| Macula Lutea | 19 | 2025 | 47 | 5.190 |
Why?
|
| Retinal Diseases | 19 | 2026 | 179 | 4.980 |
Why?
|
| Retinal Detachment | 16 | 2025 | 71 | 4.710 |
Why?
|
| Diabetes Mellitus | 19 | 2024 | 922 | 4.570 |
Why?
|
| Vitrectomy | 26 | 2025 | 91 | 4.540 |
Why?
|
| Retinal Vein Occlusion | 18 | 2025 | 28 | 4.470 |
Why?
|
| Antibodies, Monoclonal, Humanized | 23 | 2024 | 558 | 4.290 |
Why?
|
| Retinal Vessels | 24 | 2024 | 78 | 4.220 |
Why?
|
| Choroidal Neovascularization | 12 | 2023 | 34 | 4.130 |
Why?
|
| Retinal Perforations | 10 | 2024 | 25 | 3.590 |
Why?
|
| Laser Coagulation | 18 | 2025 | 130 | 3.510 |
Why?
|
| Bevacizumab | 21 | 2026 | 80 | 3.080 |
Why?
|
| Retina | 22 | 2023 | 492 | 2.470 |
Why?
|
| Choroid | 9 | 2025 | 36 | 2.270 |
Why?
|
| Glucocorticoids | 11 | 2025 | 387 | 2.200 |
Why?
|
| Humans | 258 | 2026 | 132083 | 2.190 |
Why?
|
| Aged | 99 | 2025 | 21404 | 2.130 |
Why?
|
| Scleral Buckling | 9 | 2022 | 13 | 2.070 |
Why?
|
| Middle Aged | 107 | 2026 | 28922 | 2.020 |
Why?
|
| Endophthalmitis | 7 | 2016 | 68 | 1.980 |
Why?
|
| Follow-Up Studies | 45 | 2026 | 5399 | 1.980 |
Why?
|
| Aged, 80 and over | 49 | 2025 | 7119 | 1.760 |
Why?
|
| Fundus Oculi | 21 | 2025 | 64 | 1.710 |
Why?
|
| Prospective Studies | 48 | 2025 | 6530 | 1.680 |
Why?
|
| Male | 126 | 2026 | 64904 | 1.630 |
Why?
|
| Treatment Outcome | 60 | 2026 | 13014 | 1.630 |
Why?
|
| Photography | 6 | 2022 | 87 | 1.580 |
Why?
|
| Female | 131 | 2026 | 70664 | 1.570 |
Why?
|
| Peptides, Cyclic | 2 | 2023 | 52 | 1.510 |
Why?
|
| Ischemia | 10 | 2021 | 373 | 1.440 |
Why?
|
| Retrospective Studies | 60 | 2026 | 17367 | 1.330 |
Why?
|
| Retinal Pigment Epithelium | 6 | 2025 | 38 | 1.310 |
Why?
|
| Vitreous Detachment | 3 | 2024 | 11 | 1.290 |
Why?
|
| Complement Inactivating Agents | 4 | 2023 | 12 | 1.280 |
Why?
|
| Complement C3 | 4 | 2023 | 51 | 1.230 |
Why?
|
| Fovea Centralis | 4 | 2020 | 11 | 1.140 |
Why?
|
| Endothelial Growth Factors | 12 | 2023 | 53 | 1.130 |
Why?
|
| Eye Infections, Bacterial | 3 | 2016 | 86 | 1.130 |
Why?
|
| Retinal Vasculitis | 4 | 2023 | 8 | 1.110 |
Why?
|
| Triamcinolone Acetonide | 4 | 2024 | 34 | 1.090 |
Why?
|
| Double-Blind Method | 17 | 2025 | 1653 | 1.080 |
Why?
|
| Subretinal Fluid | 7 | 2024 | 11 | 1.040 |
Why?
|
| Nerve Fibers | 3 | 2025 | 76 | 0.960 |
Why?
|
| Retinal Telangiectasis | 3 | 2025 | 5 | 0.960 |
Why?
|
| Adult | 53 | 2026 | 31544 | 0.940 |
Why?
|
| Epiretinal Membrane | 4 | 2024 | 14 | 0.940 |
Why?
|
| Disease Progression | 16 | 2025 | 2224 | 0.940 |
Why?
|
| Peripherins | 1 | 2024 | 2 | 0.910 |
Why?
|
| Biomarkers | 15 | 2025 | 3377 | 0.880 |
Why?
|
| Fluocinolone Acetonide | 4 | 2020 | 6 | 0.860 |
Why?
|
| Vitreous Body | 5 | 2024 | 96 | 0.840 |
Why?
|
| Cataract | 3 | 2022 | 169 | 0.830 |
Why?
|
| Cysts | 2 | 2024 | 97 | 0.820 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2024 | 198 | 0.820 |
Why?
|
| Clinical Trials as Topic | 6 | 2025 | 1158 | 0.810 |
Why?
|
| Retinal Vein | 3 | 2022 | 9 | 0.800 |
Why?
|
| Ophthalmology | 6 | 2024 | 197 | 0.790 |
Why?
|
| Drug Delivery Systems | 3 | 2025 | 226 | 0.780 |
Why?
|
| Angiopoietin-2 | 4 | 2024 | 16 | 0.780 |
Why?
|
| Benchmarking | 1 | 2023 | 137 | 0.770 |
Why?
|
| Eye Infections, Fungal | 4 | 2014 | 73 | 0.750 |
Why?
|
| Antibodies, Bispecific | 2 | 2024 | 52 | 0.750 |
Why?
|
| Edema | 2 | 2022 | 144 | 0.710 |
Why?
|
| Carbonic Anhydrases | 11 | 2003 | 26 | 0.700 |
Why?
|
| Cataract Extraction | 3 | 2017 | 152 | 0.700 |
Why?
|
| Neovascularization, Pathologic | 7 | 2018 | 257 | 0.690 |
Why?
|
| Ophthalmic Solutions | 2 | 2011 | 90 | 0.690 |
Why?
|
| Ophthalmoscopy | 3 | 2019 | 34 | 0.680 |
Why?
|
| No-Show Patients | 1 | 2020 | 3 | 0.660 |
Why?
|
| Vision Disorders | 4 | 2023 | 217 | 0.660 |
Why?
|
| Basement Membrane | 5 | 2024 | 47 | 0.660 |
Why?
|
| Vitreoretinal Surgery | 2 | 2021 | 6 | 0.650 |
Why?
|
| Lost to Follow-Up | 1 | 2020 | 33 | 0.650 |
Why?
|
| Retinal Hemorrhage | 2 | 2017 | 24 | 0.640 |
Why?
|
| Sensory Thresholds | 1 | 2019 | 34 | 0.620 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2019 | 305 | 0.620 |
Why?
|
| Patient Dropouts | 1 | 2019 | 52 | 0.620 |
Why?
|
| Postoperative Complications | 4 | 2017 | 3144 | 0.620 |
Why?
|
| Time Factors | 12 | 2025 | 6445 | 0.600 |
Why?
|
| Choroid Diseases | 1 | 2019 | 22 | 0.600 |
Why?
|
| Retinal Neovascularization | 4 | 2026 | 18 | 0.590 |
Why?
|
| Eye Diseases | 2 | 2011 | 117 | 0.570 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 380 | 0.560 |
Why?
|
| Microaneurysm | 3 | 2023 | 3 | 0.560 |
Why?
|
| Retinal Degeneration | 3 | 2025 | 103 | 0.540 |
Why?
|
| Lasers | 2 | 2017 | 118 | 0.520 |
Why?
|
| Patient Compliance | 1 | 2019 | 473 | 0.500 |
Why?
|
| Drug Administration Schedule | 6 | 2022 | 749 | 0.500 |
Why?
|
| Retinitis | 1 | 2016 | 16 | 0.480 |
Why?
|
| Meningoencephalitis | 1 | 2016 | 22 | 0.480 |
Why?
|
| Lasers, Solid-State | 1 | 2016 | 22 | 0.480 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2024 | 1246 | 0.460 |
Why?
|
| Anti-Bacterial Agents | 5 | 2019 | 2553 | 0.460 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 128 | 0.460 |
Why?
|
| Silicone Oils | 2 | 2025 | 8 | 0.460 |
Why?
|
| Vancomycin | 1 | 2017 | 222 | 0.450 |
Why?
|
| Atrophy | 7 | 2025 | 252 | 0.450 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2018 | 156 | 0.440 |
Why?
|
| Clinical Protocols | 5 | 2022 | 240 | 0.440 |
Why?
|
| Mutation | 3 | 2025 | 6248 | 0.440 |
Why?
|
| Cell Hypoxia | 12 | 2004 | 101 | 0.440 |
Why?
|
| Povidone-Iodine | 2 | 2011 | 9 | 0.440 |
Why?
|
| Injections, Intraocular | 3 | 2024 | 10 | 0.430 |
Why?
|
| West Nile Fever | 1 | 2016 | 139 | 0.420 |
Why?
|
| Central Serous Chorioretinopathy | 2 | 2025 | 8 | 0.420 |
Why?
|
| Cryosurgery | 1 | 2013 | 49 | 0.410 |
Why?
|
| Fungi | 3 | 2014 | 76 | 0.400 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2004 | 246 | 0.400 |
Why?
|
| Precision Medicine | 2 | 2018 | 359 | 0.400 |
Why?
|
| Retinal Ganglion Cells | 2 | 2025 | 119 | 0.400 |
Why?
|
| Uveitis | 2 | 2024 | 38 | 0.390 |
Why?
|
| Transcription Factors | 10 | 2004 | 2494 | 0.380 |
Why?
|
| Choroid Neoplasms | 2 | 2013 | 18 | 0.380 |
Why?
|
| Vitreoretinopathy, Proliferative | 2 | 2022 | 7 | 0.380 |
Why?
|
| Nuclear Proteins | 9 | 2004 | 1285 | 0.370 |
Why?
|
| Young Adult | 10 | 2026 | 9935 | 0.370 |
Why?
|
| Antisepsis | 1 | 2011 | 8 | 0.370 |
Why?
|
| Mycoses | 2 | 2014 | 117 | 0.360 |
Why?
|
| Ophthalmologists | 2 | 2024 | 14 | 0.360 |
Why?
|
| Bacteria | 2 | 2016 | 522 | 0.360 |
Why?
|
| Ciliary Body | 1 | 2011 | 24 | 0.350 |
Why?
|
| Eye | 2 | 2024 | 236 | 0.350 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 271 | 0.350 |
Why?
|
| Kidney Neoplasms | 4 | 2004 | 454 | 0.350 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2004 | 377 | 0.350 |
Why?
|
| Endotamponade | 3 | 2025 | 7 | 0.340 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2004 | 493 | 0.340 |
Why?
|
| Retinitis Pigmentosa | 2 | 2025 | 96 | 0.340 |
Why?
|
| Algorithms | 6 | 2024 | 1724 | 0.340 |
Why?
|
| Uveal Neoplasms | 1 | 2011 | 57 | 0.340 |
Why?
|
| Retreatment | 4 | 2018 | 93 | 0.340 |
Why?
|
| Aging | 1 | 2018 | 1253 | 0.330 |
Why?
|
| Retinal Drusen | 3 | 2024 | 6 | 0.330 |
Why?
|
| Regression Analysis | 3 | 2022 | 796 | 0.330 |
Why?
|
| Surgical Flaps | 2 | 2024 | 192 | 0.330 |
Why?
|
| Diagnosis, Differential | 3 | 2024 | 1967 | 0.330 |
Why?
|
| Hospitals, University | 1 | 2010 | 105 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 3 | 2019 | 1038 | 0.330 |
Why?
|
| Neoplasm Proteins | 10 | 2004 | 701 | 0.320 |
Why?
|
| Cephalosporins | 1 | 2011 | 139 | 0.320 |
Why?
|
| Regional Blood Flow | 3 | 2019 | 214 | 0.320 |
Why?
|
| Drug Hypersensitivity | 1 | 2011 | 100 | 0.310 |
Why?
|
| Pharmaceutical Preparations | 3 | 2023 | 88 | 0.310 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 132 | 0.300 |
Why?
|
| DNA-Binding Proteins | 8 | 2004 | 1997 | 0.300 |
Why?
|
| Cryptococcosis | 1 | 2009 | 45 | 0.300 |
Why?
|
| Quality of Life | 4 | 2023 | 2152 | 0.300 |
Why?
|
| Adolescent | 8 | 2026 | 20532 | 0.300 |
Why?
|
| Oculomotor Nerve | 1 | 2008 | 7 | 0.300 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2008 | 8 | 0.290 |
Why?
|
| Drug Therapy, Combination | 4 | 2025 | 1176 | 0.290 |
Why?
|
| Capillary Permeability | 2 | 2020 | 77 | 0.290 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2008 | 18 | 0.290 |
Why?
|
| Risk Factors | 11 | 2024 | 10899 | 0.290 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2008 | 17 | 0.290 |
Why?
|
| Blindness | 2 | 2021 | 76 | 0.290 |
Why?
|
| Exudates and Transudates | 2 | 2021 | 22 | 0.280 |
Why?
|
| Rhabdoid Tumor | 1 | 2008 | 56 | 0.280 |
Why?
|
| Antigens, Neoplasm | 8 | 2003 | 403 | 0.280 |
Why?
|
| Corneal Ulcer | 1 | 2008 | 54 | 0.280 |
Why?
|
| Combined Modality Therapy | 8 | 2020 | 1295 | 0.280 |
Why?
|
| Vitelliform Macular Dystrophy | 2 | 2024 | 2 | 0.270 |
Why?
|
| Single-Blind Method | 2 | 2021 | 242 | 0.270 |
Why?
|
| Teratoma | 1 | 2008 | 130 | 0.270 |
Why?
|
| Cross Infection | 1 | 2010 | 343 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2002 | 2064 | 0.250 |
Why?
|
| United States | 10 | 2025 | 11630 | 0.250 |
Why?
|
| Semaphorin-3A | 1 | 2025 | 1 | 0.240 |
Why?
|
| Neuropilin-1 | 1 | 2025 | 16 | 0.240 |
Why?
|
| Drug Implants | 3 | 2025 | 44 | 0.230 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 3083 | 0.230 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2006 | 97 | 0.230 |
Why?
|
| Gene Expression Profiling | 2 | 2004 | 1879 | 0.230 |
Why?
|
| Myopia | 1 | 2006 | 133 | 0.230 |
Why?
|
| Hexokinase | 1 | 2025 | 26 | 0.230 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 3738 | 0.230 |
Why?
|
| Biomarkers, Tumor | 7 | 2008 | 1683 | 0.230 |
Why?
|
| Melanoma | 2 | 2013 | 954 | 0.220 |
Why?
|
| Intraocular Pressure | 2 | 2024 | 135 | 0.220 |
Why?
|
| Oxygen | 6 | 2018 | 571 | 0.220 |
Why?
|
| Aqueous Humor | 2 | 2022 | 28 | 0.220 |
Why?
|
| Angiopoietins | 2 | 2021 | 21 | 0.220 |
Why?
|
| Drug Approval | 1 | 2024 | 45 | 0.220 |
Why?
|
| Dexamethasone | 1 | 2025 | 274 | 0.210 |
Why?
|
| Complement C5 | 1 | 2023 | 7 | 0.210 |
Why?
|
| Cross-Over Studies | 1 | 2025 | 324 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 9 | 2004 | 1047 | 0.210 |
Why?
|
| Ligases | 2 | 2000 | 40 | 0.210 |
Why?
|
| Cyclin D1 | 1 | 2004 | 113 | 0.210 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2002 | 75 | 0.210 |
Why?
|
| Hypoxia | 4 | 2004 | 259 | 0.210 |
Why?
|
| Entropy | 1 | 2023 | 29 | 0.210 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 158 | 0.210 |
Why?
|
| Meta-Analysis as Topic | 1 | 2024 | 172 | 0.210 |
Why?
|
| Photochemotherapy | 2 | 2022 | 41 | 0.210 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2023 | 6 | 0.210 |
Why?
|
| Aptamers, Nucleotide | 1 | 2023 | 36 | 0.200 |
Why?
|
| Drainage | 1 | 2025 | 265 | 0.200 |
Why?
|
| Evidence-Based Medicine | 2 | 2024 | 669 | 0.200 |
Why?
|
| Traction | 1 | 2022 | 9 | 0.190 |
Why?
|
| Drug Resistance | 2 | 2013 | 252 | 0.190 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 9 | 2004 | 101 | 0.190 |
Why?
|
| Eye Neoplasms | 2 | 2013 | 46 | 0.190 |
Why?
|
| Prone Position | 1 | 2022 | 33 | 0.190 |
Why?
|
| Porphyrins | 1 | 2022 | 18 | 0.190 |
Why?
|
| Hypoxia-Inducible Factor 1 | 8 | 2004 | 19 | 0.190 |
Why?
|
| Delphi Technique | 1 | 2023 | 240 | 0.190 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 251 | 0.180 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2024 | 390 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2026 | 344 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2012 | 332 | 0.180 |
Why?
|
| Biomedical Research | 2 | 2019 | 550 | 0.180 |
Why?
|
| Equipment Design | 2 | 2020 | 611 | 0.180 |
Why?
|
| Cornea | 1 | 2006 | 597 | 0.180 |
Why?
|
| Confidence Intervals | 1 | 2021 | 277 | 0.180 |
Why?
|
| Postoperative Period | 2 | 2020 | 333 | 0.180 |
Why?
|
| Blood-Retinal Barrier | 2 | 2020 | 3 | 0.170 |
Why?
|
| Computer Systems | 1 | 2021 | 38 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 1672 | 0.170 |
Why?
|
| Cytokines | 3 | 2022 | 1366 | 0.170 |
Why?
|
| Registries | 3 | 2023 | 1589 | 0.170 |
Why?
|
| Videoconferencing | 1 | 2020 | 22 | 0.170 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2020 | 65 | 0.170 |
Why?
|
| Consensus | 1 | 2023 | 656 | 0.160 |
Why?
|
| Fractals | 1 | 2019 | 2 | 0.160 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 19 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 211 | 0.160 |
Why?
|
| Microcirculation | 2 | 2019 | 117 | 0.160 |
Why?
|
| Recurrence | 3 | 2019 | 1454 | 0.150 |
Why?
|
| Income | 1 | 2020 | 137 | 0.150 |
Why?
|
| Congresses as Topic | 1 | 2020 | 185 | 0.150 |
Why?
|
| Biological Products | 1 | 2021 | 137 | 0.150 |
Why?
|
| Insurance Coverage | 1 | 2020 | 124 | 0.150 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1494 | 0.150 |
Why?
|
| Early Diagnosis | 1 | 2019 | 198 | 0.150 |
Why?
|
| Antifungal Agents | 3 | 2014 | 313 | 0.150 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 122 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 552 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 152 | 0.140 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2019 | 85 | 0.140 |
Why?
|
| Necrosis | 7 | 2004 | 210 | 0.140 |
Why?
|
| Proteins | 2 | 2000 | 1038 | 0.140 |
Why?
|
| Vision, Low | 1 | 2017 | 15 | 0.140 |
Why?
|
| Visual Prosthesis | 1 | 2017 | 6 | 0.140 |
Why?
|
| Prognosis | 9 | 2025 | 5006 | 0.140 |
Why?
|
| Ultrasonography | 3 | 2024 | 989 | 0.140 |
Why?
|
| Breast Neoplasms | 5 | 2004 | 2682 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 299 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1306 | 0.130 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 16 | 0.130 |
Why?
|
| Legislation, Drug | 1 | 2016 | 9 | 0.130 |
Why?
|
| Administration, Topical | 1 | 2016 | 140 | 0.120 |
Why?
|
| Beryllium | 1 | 2016 | 3 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 154 | 0.120 |
Why?
|
| Cohort Studies | 6 | 2022 | 5148 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2002 | 210 | 0.120 |
Why?
|
| Lung Neoplasms | 4 | 2012 | 1540 | 0.120 |
Why?
|
| Therapeutic Equivalency | 1 | 2015 | 12 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 479 | 0.120 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2015 | 42 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 378 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 389 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2018 | 326 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2023 | 52 | 0.110 |
Why?
|
| Signal Transduction | 4 | 2025 | 4725 | 0.110 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 3 | 2004 | 37 | 0.110 |
Why?
|
| Fluconazole | 2 | 2014 | 50 | 0.100 |
Why?
|
| Amphotericin B | 2 | 2014 | 91 | 0.100 |
Why?
|
| von Hippel-Lindau Disease | 3 | 2002 | 20 | 0.100 |
Why?
|
| History, 18th Century | 1 | 2013 | 70 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 764 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2020 | 802 | 0.100 |
Why?
|
| Carbonic Anhydrase IX | 8 | 2003 | 13 | 0.100 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 105 | 0.090 |
Why?
|
| Anterior Chamber | 1 | 2012 | 33 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2016 | 1121 | 0.090 |
Why?
|
| Electroretinography | 2 | 2025 | 121 | 0.090 |
Why?
|
| Chlorhexidine | 1 | 2011 | 47 | 0.090 |
Why?
|
| Telemedicine | 1 | 2018 | 506 | 0.090 |
Why?
|
| Lymphokines | 2 | 2002 | 66 | 0.090 |
Why?
|
| Refraction, Ocular | 1 | 2013 | 217 | 0.090 |
Why?
|
| Drug Costs | 1 | 2011 | 65 | 0.090 |
Why?
|
| Liver Function Tests | 1 | 2011 | 103 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 2922 | 0.090 |
Why?
|
| Retinopathy of Prematurity | 1 | 2011 | 64 | 0.090 |
Why?
|
| Laser Therapy | 1 | 2013 | 232 | 0.090 |
Why?
|
| Glucose | 1 | 2015 | 878 | 0.080 |
Why?
|
| Florida | 1 | 2010 | 80 | 0.080 |
Why?
|
| Decision Making | 1 | 2015 | 694 | 0.080 |
Why?
|
| Acute Disease | 2 | 2010 | 1161 | 0.080 |
Why?
|
| Penicillins | 1 | 2011 | 155 | 0.080 |
Why?
|
| Neoplasms | 2 | 2004 | 2952 | 0.080 |
Why?
|
| Child | 3 | 2024 | 25761 | 0.080 |
Why?
|
| Immunohistochemistry | 6 | 2003 | 1722 | 0.080 |
Why?
|
| Flucytosine | 1 | 2009 | 17 | 0.080 |
Why?
|
| Cryptococcus neoformans | 1 | 2009 | 23 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2021 | 84 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 161 | 0.080 |
Why?
|
| In Situ Hybridization | 4 | 2004 | 470 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2011 | 369 | 0.070 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2008 | 5 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 314 | 0.070 |
Why?
|
| Subarachnoid Space | 1 | 2008 | 25 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2008 | 663 | 0.070 |
Why?
|
| Mesencephalon | 1 | 2008 | 39 | 0.070 |
Why?
|
| Incidence | 1 | 2016 | 3365 | 0.070 |
Why?
|
| Eye Enucleation | 1 | 2008 | 45 | 0.070 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2008 | 51 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 3020 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2008 | 377 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2001 | 764 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2008 | 364 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2003 | 1085 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3417 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2002 | 540 | 0.060 |
Why?
|
| Body Weights and Measures | 1 | 2006 | 39 | 0.060 |
Why?
|
| Capillaries | 2 | 2017 | 71 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 2 | 2001 | 615 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2008 | 320 | 0.060 |
Why?
|
| Hydrocephalus | 1 | 2008 | 276 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 1452 | 0.060 |
Why?
|
| Transfection | 3 | 2004 | 999 | 0.060 |
Why?
|
| Phenotype | 3 | 2025 | 4541 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2024 | 3854 | 0.060 |
Why?
|
| Prevalence | 2 | 2025 | 2657 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 3 | 2003 | 381 | 0.060 |
Why?
|
| Immunoblotting | 2 | 2004 | 304 | 0.050 |
Why?
|
| Suspensions | 1 | 2024 | 9 | 0.050 |
Why?
|
| Pandemics | 2 | 2023 | 1186 | 0.050 |
Why?
|
| Search Engine | 1 | 2023 | 11 | 0.050 |
Why?
|
| RNA, Messenger | 4 | 2004 | 2679 | 0.050 |
Why?
|
| Organic Chemicals | 1 | 2023 | 59 | 0.050 |
Why?
|
| Plasmids | 2 | 2004 | 459 | 0.050 |
Why?
|
| Vitreous Hemorrhage | 1 | 2023 | 10 | 0.050 |
Why?
|
| Inflammation | 2 | 2022 | 1521 | 0.050 |
Why?
|
| Equivalence Trials as Topic | 1 | 2023 | 24 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2023 | 10 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2025 | 825 | 0.050 |
Why?
|
| Nephrons | 1 | 2002 | 18 | 0.050 |
Why?
|
| Neurofibromin 2 | 1 | 2022 | 11 | 0.050 |
Why?
|
| Indocyanine Green | 2 | 2015 | 63 | 0.050 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2002 | 26 | 0.050 |
Why?
|
| Syringes | 1 | 2022 | 24 | 0.050 |
Why?
|
| Cell Division | 2 | 2001 | 744 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2004 | 880 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2022 | 37 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2023 | 229 | 0.050 |
Why?
|
| Pentosan Sulfuric Polyester | 1 | 2021 | 1 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 1305 | 0.050 |
Why?
|
| Cell Adhesion Molecule-1 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 341 | 0.040 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2021 | 9 | 0.040 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2021 | 26 | 0.040 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2021 | 38 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2021 | 40 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 2141 | 0.040 |
Why?
|
| RNA | 2 | 2004 | 549 | 0.040 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2001 | 30 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2025 | 856 | 0.040 |
Why?
|
| Pedigree | 1 | 2025 | 1725 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2002 | 1046 | 0.040 |
Why?
|
| Ribonucleases | 1 | 2000 | 45 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1347 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 131 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2000 | 28 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2001 | 85 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 2001 | 56 | 0.040 |
Why?
|
| Organ Size | 1 | 2022 | 447 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2001 | 92 | 0.040 |
Why?
|
| Machine Learning | 1 | 2024 | 347 | 0.040 |
Why?
|
| Slit Lamp Microscopy | 1 | 2020 | 6 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 311 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2001 | 201 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 273 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 1386 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2000 | 44 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2001 | 714 | 0.040 |
Why?
|
| Half-Life | 1 | 2020 | 161 | 0.040 |
Why?
|
| Observation | 1 | 2020 | 43 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2001 | 109 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2003 | 573 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 422 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2019 | 65 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2000 | 365 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2004 | 815 | 0.040 |
Why?
|
| Breast | 1 | 2001 | 216 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2000 | 1294 | 0.040 |
Why?
|
| Calcinosis | 1 | 2001 | 191 | 0.040 |
Why?
|
| Medicare | 1 | 2023 | 448 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2024 | 720 | 0.040 |
Why?
|
| Protein Binding | 2 | 2020 | 1735 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 436 | 0.040 |
Why?
|
| Gene Expression Regulation | 4 | 2004 | 2444 | 0.040 |
Why?
|
| Cells | 1 | 1999 | 24 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 237 | 0.040 |
Why?
|
| Genotype | 1 | 2025 | 2706 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 743 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 686 | 0.040 |
Why?
|
| Specialization | 1 | 2019 | 80 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2018 | 36 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 697 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 2019 | 86 | 0.040 |
Why?
|
| Carcinoma | 1 | 2000 | 300 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 292 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 518 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2000 | 771 | 0.030 |
Why?
|
| Caveolins | 1 | 1997 | 16 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 113 | 0.030 |
Why?
|
| Infant | 2 | 2011 | 13040 | 0.030 |
Why?
|
| European Union | 1 | 2016 | 13 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 415 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 611 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2168 | 0.030 |
Why?
|
| Gene Expression | 1 | 2001 | 1564 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 405 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 827 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 680 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2015 | 20 | 0.030 |
Why?
|
| Voriconazole | 1 | 2014 | 34 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 670 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1838 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2003 | 1569 | 0.030 |
Why?
|
| COS Cells | 2 | 2004 | 269 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1997 | 634 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1351 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 277 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 307 | 0.030 |
Why?
|
| Light Coagulation | 1 | 2013 | 23 | 0.030 |
Why?
|
| RNA, Neoplasm | 2 | 2004 | 137 | 0.030 |
Why?
|
| Visual Fields | 1 | 2014 | 145 | 0.030 |
Why?
|
| Nevus | 1 | 2013 | 35 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 897 | 0.030 |
Why?
|
| Hyperthermia, Induced | 1 | 2013 | 59 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2002 | 250 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2022 | 14719 | 0.020 |
Why?
|
| Retinoblastoma | 1 | 2013 | 113 | 0.020 |
Why?
|
| Hemangioma | 1 | 2013 | 97 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 830 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2014 | 391 | 0.020 |
Why?
|
| Retinal Neoplasms | 1 | 2013 | 102 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2013 | 158 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 64 | 0.020 |
Why?
|
| Enzyme Induction | 2 | 2001 | 97 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 827 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 861 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2009 | 77 | 0.020 |
Why?
|
| Fluorescence | 1 | 2009 | 103 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1997 | 1596 | 0.020 |
Why?
|
| Response Elements | 2 | 1999 | 98 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1408 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 1173 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2004 | 21 | 0.010 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2004 | 35 | 0.010 |
Why?
|
| Immune Sera | 1 | 2004 | 89 | 0.010 |
Why?
|
| Mixed Function Oxygenases | 1 | 2004 | 36 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 59 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 383 | 0.010 |
Why?
|
| Doxycycline | 1 | 2004 | 121 | 0.010 |
Why?
|
| Animals | 5 | 2004 | 34951 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 19 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 329 | 0.010 |
Why?
|
| Apoptosis | 2 | 2002 | 1904 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2002 | 33 | 0.010 |
Why?
|
| RNA Interference | 1 | 2004 | 516 | 0.010 |
Why?
|
| RNA Probes | 1 | 2002 | 30 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2002 | 27 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 222 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2002 | 43 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 124 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 691 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 679 | 0.010 |
Why?
|
| Thymidine Phosphorylase | 1 | 2001 | 13 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 1051 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 637 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2001 | 38 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2001 | 53 | 0.010 |
Why?
|
| England | 1 | 2001 | 63 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2001 | 87 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2002 | 331 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2002 | 180 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2001 | 145 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 492 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 437 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2001 | 295 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1292 | 0.010 |
Why?
|
| Mice | 3 | 2004 | 18565 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 1443 | 0.010 |
Why?
|
| Cobalt | 1 | 1999 | 18 | 0.010 |
Why?
|
| Iron Chelating Agents | 1 | 1999 | 15 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 1425 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 2730 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 955 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 1999 | 85 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 623 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 1999 | 112 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8539 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 1999 | 251 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2001 | 549 | 0.010 |
Why?
|
| Survival Rate | 1 | 2003 | 2184 | 0.010 |
Why?
|
| Genes, fos | 1 | 1997 | 15 | 0.010 |
Why?
|
| Mammals | 1 | 1999 | 271 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1999 | 732 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1997 | 124 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 1997 | 50 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 1050 | 0.010 |
Why?
|
| Genes, ras | 1 | 1997 | 100 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2001 | 1367 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2001 | 816 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2001 | 2303 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 1997 | 430 | 0.010 |
Why?
|
| Lung | 1 | 2003 | 1556 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2001 | 1017 | 0.010 |
Why?
|